Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2024-11-03 Regulatory Filings
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - NYR 6 pages 18.6KB
Regulatory Filings Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the securities to be quoted, issue dates, and related information about the securities issued. This type of document is a regulatory announcement related to capital markets and securities listing, specifically an application for quotation of securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement but a formal regulatory filing to the exchange. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-11-03 English
Cleansing Statement 2 pages 245.7KB
Regulatory Filings Classification · 95% confidence The document is titled 'Cleansing Statement' and references an Appendix 2A lodged on the same date, related to the issuance of CHESS Depositary Interests (CDIs) as part of a Capital Raising Program. It cites compliance with sections of the Corporations Act 2001 (Cth) and provides legal assurances about disclosure and excluded information. The document is short (3184 characters) and primarily serves as a regulatory notice about the issuance of securities without a disclosure document under specific legal provisions. It does not contain financial statements, management discussion, or detailed financial data. This type of document is a regulatory announcement related to capital raising but is not a full capital/financing update report. Given the nature and content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-11-03 English
Nyrada Successfully Raises $3.36 Million via Placement 5 pages 273.8KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about Nyrada Inc. successfully raising $3.36 million via a placement of equity capital, including details about the placement price, use of proceeds, director participation, and a securities purchase plan (SPP) to raise additional funds. It discusses fundraising activities, capital structure changes, and related timelines. There is no financial report, earnings data, or management discussion of financial results. The content focuses on capital raising and financing activities. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is over 11,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2024-10-27 English
Investor Presentation 20 pages 1.9MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation October 2024' and contains detailed information about the company's drug development pipeline, clinical trial plans, financial snapshot, leadership, and investment proposition. It includes forward-looking statements, use of funds, and strategic partnerships. The content is typical of a presentation prepared for investors to provide an overview of the company's business, strategy, and financial position. There are no full financial statements or detailed quarterly or annual financial results, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a regulatory filing, earnings release, or other categories such as M&A or legal proceedings. The document is clearly a presentation aimed at investors, matching the definition of an Investor Presentation (IP). The length (15,000 characters) and detailed content support this classification with high confidence.
2024-10-27 English
Proposed issue of securities - NYR 5 pages 18.9KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and contains detailed information about a proposed placement or other type of securities issue by NYRADA INC. It includes specifics such as the number of securities to be issued, issue price, conditions including shareholder approval, timetable, fees, and purpose of the issue. The document is a formal announcement of a capital raising event and does not contain financial statements or earnings data. It is not a report but an announcement related to capital structure changes. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (6294 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2024-10-27 English
Proposed issue of securities - NYR 10 pages 33.3KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and contains detailed information about a proposed securities issue by NYRADA INC., including the number and type of securities, offer price, timetable, conditions, fees, and purpose of the capital raise. It references ASX Listing Rules and placement capacities, typical of capital raising announcements. The document is about a securities purchase plan and placement, describing the issuance of new shares and options. It does not contain financial statements or earnings data, nor is it a report or transcript. It is a detailed announcement of a capital raising event and securities issuance, fitting the Capital/Financing Update category.
2024-10-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.